=>
Uploading C:\Program Files\Stnexp\Queries\10553955a.str





chain nodes :
6 7 8 9 10 11 12 14 16 17 18
ring nodes :
1 2 3 4 5
chain bonds :
1-16 2-18 4-6 6-7 6-11 7-8 7-17 8-9 8-12 9-10 9-14
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 2-18 3-4 4-5 6-7 6-11 7-8 8-12 9-10 9-14
exact bonds :
1-16 4-6 7-17 8-9

G1:H,CH3,CH2,CH,Et,n-Pr,i-Pr,n-Bu,i-Bu

G2:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS
11:CLASS 12:CLASS 14:CLASS 16:CLASS 17:CLASS 18:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 H,Me,CH2,CH,Et,n-Pr,i-Pr,n-Bu,i-Bu
G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:09:01 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2491 TO ITERATE

100.0% PROCESSED 2491 ITERATIONS 24 ANSWERS
SEARCH TIME: 00.00.01

L2 24 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.78

FILE 'CAPLUS' ENTERED AT 14:09:09 ON 11 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 11 Feb 2008 VOL 148 ISS 7
FILE LAST UPDATED: 10 Feb 2008 (20080210/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3 6 L2

=> d l3 1-6 ibib abs hitstr

L3 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:817369 CAPLUS Full-text
DOCUMENT NUMBER: 145:249516
TITLE: Preparation of peptide boronic acids as proteasome inhibitors
INVENTOR(S): Oliva, Ambrogio; Bernardnini, Raffaella; D'Arasmo, Germano; Cassara, Paolo G.; Bernareggi, Alberto; Menta, Ernesto
PATENT ASSIGNEE(S): Cephalon, Inc., USA
SOURCE: PCT Int. Appl., 159pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006086600	A1	20060817	WO 2006-US4664		20060210
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
US 2006189806	A1	20060824	US 2006-351193		20060209
AU 2006213814	A1	20060817	AU 2006-213814		20060210
CA 2597273	A1	20060817	CA 2006-2597273		20060210
EP 1846424	A1	20071024	EP 2006-734698		20060210
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
IN 2007KN02726	A	20070831	IN 2007-KN2726		20070724
CN 101120006	A	20080206	CN 2006-80004689		20070813
PRIORITY APPLN. INFO.:			US 2005-652370P	P	20050211
			US 2006-351193	A	20060209
			WO 2006-US4664	W	20060210

OTHER SOURCE(S): MARPAT 145:249516
GI



I

AB The invention provides peptide boronic acid derivs. Hy-CONHCHR2CONHCH(CH2CHMe2)B(OR1)2 [R1 is H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl or may combine to form a ring; R2 is CHMeOH or aminomethyl; Hy is an optionally-substituted nitrogen-containing heterocyclic group optionally fused with an aryl or heteroaryl group (with provisos)] that can modulate apoptosis by inhibition of proteasome activity and are for use in treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity. Thus, compound I was prepared by a multistep sequence starting with reaction of (+)-pinanediol with 2-methylpropylboronic

acid, conversion of the product to a leucine boronate analog, and subsequent acylations by Boc-protected L-threonine and 6-phenyl-2-pyrazinecarboxylic acid.

IT 906089-74-5P 906090-30-0P 906090-65-1P
906090-90-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide boronic acids as proteasome inhibitors)

RN 906089-74-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[(1S,2R)-1-[[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]carbonyl]-2-hydroxypropyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 906090-30-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[(1S)-2-[[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]amino]-1-[[(4-methylbenzoyl)amino]methyl]-2-oxoethyl]-5-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 906090-65-1 CAPLUS
CN Boronic acid, [(1R)-1-[[(2S,3R)-3-hydroxy-1-oxo-2-[[(5-phenyl-1H-pyrazol-3-yl)carbonyl]amino]butyl]amino]-3-methylbutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 906090-90-2 CAPLUS
CN Boronic acid, [(1R)-3-methyl-1-[[(2S)-3-[(4-methylbenzoyl)amino]-1-oxo-2-[[(5-phenyl-1H-pyrazol-3-yl)carbonyl]amino]propyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:216605 CAPLUS Full-text
DOCUMENT NUMBER: 142:316496
TITLE: Preparation of substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
INVENTOR(S): Carter, Percy H.; Cherney, Robert J.; Batt, Douglas G.; Brown, Gregory D.; Duncia, John V.; Gardner, Daniel S.; Yang, Michael G.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 440 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020899	A2	20050310	WO 2004-US27195	20040820
WO 2005020899	A3	20050630		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005054626	A1	20050310	US 2004-923538		20040819
EP 1656138	A2	20060517	EP 2004-781805		20040820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2007502842	T	20070215	JP 2006-524091		20040820
NO 2006000719	A	20060427	NO 2006-719		20060214
PRIORITY APPLN. INFO.:			US 2003-496974P	P	20030821
			US 2004-923538	A	20040819
			WO 2004-US27195	W	20040820

OTHER SOURCE(S): MARPAT 142:316496

GI



I



II

AB Title compds. I [Ring B = saturated or partially unsatd., (un)substituted cycloalkyl or heterocycle; X = O or S; Z = CO, CONR8, NR8, NR8CO, etc.; R1 = H, (un)substituted-alkyl, -alkenyl, -aryl, etc.; R2 = (un)substituted aryl or heteroaryl; R3 = H, Me, or Et; R8 = H, alkyl, or cycloalkyl; R10 and R10a independently = H or (un)substituted alkyl; R11 = H, alkyl, etc.; R12 = H, alkyl, (un)substituted carbocycle; m = 0-1; n = 1 or 2], or pharmaceutically acceptable salt forms thereof, are prepared and disclosed as modulators of chemokine receptor activity. Thus, e.g., II was prepared by amidation of trans-4-aminocyclohexanol hydrochloride with (3-trifluoromethylbenzoylamino)acetic acid followed by mesylation, substitution with sodium azide and subsequent reduction I were deemed active (IC50 value of 20 μM or less) in antagonism of MCP-1 binding to human peripheral blood mononuclear cells. As modulators of MCP-1, I should prove useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

IT 847953-11-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cycloalkylamine derivs. with chemokine receptor activity)

RN 847953-11-1 CAPLUS

CN 1H-Pyrazole-3-carboxamide, N-[2-[[4-[(1,1-dimethylethyl)amino]cyclohexyl]amino]-2-oxoethyl]-5-tricyclo[3.3.1.13,7]dec-1-yl- (CA INDEX NAME)



L3 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:965056 CAPLUS Full-text

DOCUMENT NUMBER: 141:411216

TITLE: Preparation of amino acid pyrazolecarboxamides as heat shock protein 90 (HSP90) inhibitors for the treatment of cancer

INVENTOR(S): Barril-Alonso, Xavier; Dymock, Brian William; Drysdale, Martin James

PATENT ASSIGNEE(S): Vernalis Cambridge Limited, UK; Cancer Research Technology Ltd.; The Institute of Cancer Research

SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096212	A1	20041111	WO 2004-GB1740	20040423
WO 2004096212	A9	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1620090	A1	20060201	EP 2004-729149	20040423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2006524673	T	20061102	JP 2006-506168	20040423
US 2007072855	A1	20070329	US 2006-553955	20060810

PRIORITY APPLN. INFO.: GB 2003-9637 A 20030428
WO 2004-GB1740 W 20040423

OTHER SOURCE(S): MARPAT 141:411216
GI



I

AB Use of title compds. [I; R1 = Ar1(Alk1)pZr(Alk2)sQ; Ar1 = (substituted) aryl, heteroaryl; Alk1, Alk2 = alkylene, alkylene; p, r, s = 0, 1; Z = O, S, CO, CS, SO2, CO2, CONRa, NRa, etc.; Ra = H, alkyl; Q = H, (substituted) carbocyclyl, heterocyclyl; R2 = Ar1(Alk1)pZr(Alk2)sQ, carboxamide, (substituted) carbocyclyl, heterocyclyl; R3 = H, (hydroxy-substituted) Me, Et, Pr; X = OR4, NR4R5; R4, R5 = H, (substituted) alkyl; NR4R5 = 5-8 membered heterocyclyl], for inhibition of HSP90 activity is claimed. Thus, 6-chloro-7-hydroxy-3-(4-methoxyphenyl)-4-oxo-4H-chromene-2- carboxylic acid (preparation given) was heated with N2H4.H2O and aqueous NaHCO3 in EtOH at 70° for 2 h to give 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4- methoxyphenyl)-2H-pyrazole-3-carboxylic acid. This was stirred overnight with 1-hydroxybenzotriazole hydrate, N-ethyl-N'-(3- dimethylaminopropyl)carbodiimide hydrochloride, N-methylmorpholine, and racemic alanine Me ester hydrochloride in CH2Cl2 at 0° to room temperature to give racemic alanine Me ester 5-(5-chloro-2,4-dihydroxyphenyl)-4- (4-methoxyphenyl)-2H-pyrazole-3-carboxamide. The latter in a fluorescence polarization assay showed IC50 <10 μM for binding to HSP90.

IT 791103-68-9P 791103-69-0P 791103-70-3P
791103-71-4P 791103-72-5P 791103-73-6P
791103-74-7P 791103-76-9P 791103-77-0P
791103-78-1P 791103-79-2P 791103-80-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid pyrazolecarboxamides as heat shock protein 90 (HSP90) inhibitors for the treatment of cancer)

RN 791103-68-9 CAPLUS
CN Alanine, N-[[5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]-, methyl ester (CA INDEX NAME)



RN 791103-69-0 CAPLUS
CN Alanine, N-[[5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]- (CA INDEX NAME)



RN 791103-70-3 CAPLUS
CN Glycine, N-[[5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]-, methyl ester (CA INDEX NAME)



RN 791103-71-4 CAPLUS
CN D-Alanine, N-[[5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-72-5 CAPLUS
CN L-Alanine, N-[[5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-73-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[(1R)-2-amino-1-methyl-2-oxoethyl]-5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-74-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[(1S)-2-amino-1-methyl-2-oxoethyl]-5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-76-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-N-[(1R)-1-methyl-2-(methylamino)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-77-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-N-[(1R)-1-methyl-2-[(1-methylethyl)amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-78-1 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(5-chloro-2,4-dihydroxyphenyl)-N-[(1R)-2-[[2-(dimethylamino)ethyl]amino]-1-methyl-2-oxoethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-79-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(5-chloro-2,4-dihydroxyphenyl)-4-(4-methoxyphenyl)-N-[(1R)-1-methyl-2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-80-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(5-chloro-2,4-dihydroxyphenyl)-N-[(1R)-2-(ethylamino)-1-methyl-2-oxoethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 791103-83-8P 791103-84-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid pyrazolecarboxamides as heat shock protein 90 (HSP90) inhibitors for the treatment of cancer)
RN 791103-83-8 CAPLUS
CN D-Alanine, N-[[5-[5-chloro-2,4-bis[[(1,1-dimethylethoxy)carbonyl]oxy]phenyl]-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 791103-84-9 CAPLUS
CN D-Alanine, N-[[5-[5-chloro-2,4-bis[[(1,1-dimethylethoxy)carbonyl]oxy]phenyl]-4-(4-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:675727 CAPLUS Full-text
DOCUMENT NUMBER: 141:207521
TITLE: Preparation of bis(hetero)aryl carboxamides as PGI2 antagonists for the treatment of urological disorders.
INVENTOR(S): Murata, Toshiki; Shintani, Takuya; Umeda, Masaomi; Lino, Takashi; Moriwaki, Toshiya
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004069805	A1	20040819	WO 2004-EP711		20040128
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2515235	A1	20040819	CA 2004-2515235		20040128
EP 1594846	A1	20051116	EP 2004-705785		20040128
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006517211	T	20060720	JP 2006-501629		20040128
US 2006247260	A1	20061102	US 2006-544033		20060626
PRIORITY APPLN. INFO.:			EP 2003-2607	A	20030210
			WO 2004-EP711	W	20040128

OTHER SOURCE(S): MARPAT 141:207521
GI



I



II

AB Title compds. I [X = -Ar1-Ar2-R1; Ar1, Ar2 = Ph, 5 or 6-membered heteroarom. ring containing 1-4 heteroatoms, e.g., O, N, S; R1 = OR11, SR11, SOR11, etc.; R11 = (un)saturated alkyl with provisos; R2 = H, OH, halo, etc.; R3 = H, OH, halo, etc.; R4 = H, OH, halo, etc.; R5 = H, halo, CN, etc.; R6 = carboxy, tetrazolyl] and their pharmaceutically acceptable salts were prepared For example, ester hydrolysis of Me ester II (Z = OMe), e.g., prepared from 4-hydroxyacetophenone in 5-steps, afforded propionic acid II (Z = OH) in 77% yield. In PGI2 receptor binding/cAMP assays, 48-examples of compds. I exhibited in vitro activity of < 1 μM. Compds. I are claimed useful for the treatment of urol. disorders.

IT 742057-80-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bis(hetero)aryl carboxamides as PGI2 antagonists for the treatment of urol. disorders.)

RN 742057-80-3 CAPLUS

CN L-Phenylalanine, N-[[5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 742058-29-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bis(hetero)aryl carboxamides as PGI2 antagonists for the treatment of urol. disorders.)

RN 742058-29-3 CAPLUS

CN L-Phenylalanine, N-[[5-[4-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl]carbonyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1986:406505 CAPLUS Full-text
DOCUMENT NUMBER: 105:6505
ORIGINAL REFERENCE NO.: 105:1213a,1216a
TITLE: Phenylpyrazole derivatives
INVENTOR(S): Isekawa, Junichi; Shaku, Kunio; Sawada, Masahiro; Fukuda, Minoru; Yamada, Toshihiro; Oki, Masahiko; Matsuo, Yoshio
PATENT ASSIGNEE(S): Morishita Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61040266	A	19860226	JP 1984-163327	19840801

PRIORITY APPLN. INFO.: JP 1984-163327 19840801
GI



I

AB The title compds. [I; R = H, lower alkyl, (un)esterified carboxyalkyl, Ph, PhCh2; R1 = (un)esterified CO2H, carbamoyl, (un)substituted lower alkyl; R2 = alkyl, (4- or α-substituted) PhCH2], useful as hypolipemics (no data), were prepared Thus, cyclocondensation of p- ClC6H4CH2OC6H4COCH:C(OMe)CO2Et-p with N2N4.H2O in refluxing EtOH for 1 h gave 70% I (R = H, R1 = CO2Et, R2 = 4-ClC6H4CH2).

IT 102669-19-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as hypolipemic)

RN 102669-19-2 CAPLUS
CN Glycine, N-[[5-[4-[(4-chlorophenyl)methoxy]phenyl]-1H-pyrazol-3-yl]carbonyl]-, ethyl ester (CA INDEX NAME)



L3 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1970:415245 CAPLUS Full-text
DOCUMENT NUMBER: 73:15245
ORIGINAL REFERENCE NO.: 73:2553a,2556a
TITLE: Substances with antineoplastic activity. XLIII. Reaction of ethyl ester of N-[β-(4-methoxybenzoyl)-β-bromoacryloyl]glycine and -β-alanine with hydrazide; ethyl ester of N-[β-(4-methoxybenzoyl)-β-bromoacryloyl]glycylglycine
AUTHOR(S): Zikan, Viktor; Semonsky, Miroslav; Svatek, Emil
CORPORATE SOURCE: Vyzk. Ustav Farm. Biochem., Prague, Czech.
SOURCE: Collection of Czechoslovak Chemical Communications (1970), 35(5), 1434-9
CODEN: CCCCAK; ISSN: 0010-0765
DOCUMENT TYPE: Journal
LANGUAGE: English

AB p-MeOC6H4COCBr:CHCONH(CH2)nCO2Et (n = 1 and 2) gave pyrazoles with excess N2H4.H2O in EtOH. p-MeOC6H4COCBr:CHCONHCH2CO2H gave with H2NCH2CO2Et by the dicyclohexylcarbodiimide method p-MeOC6H4COCBr:CHCONHCH2CONHCH2CO2Et (I), which exists predominantly in the hydroxylactam form. One of the pyrazoles and I inhibited the growth of the mammary adenocarcinoma, Ehrlich ascites tumor, and Crockers sarcoma 180 by 33-47% in rats but did not prolong survival of the animals. I prolonged the survival of mice with the S 37 sarcoma by 24% but had no effect on the tumor growth. None of the compds. had any effect on the Yoshida ascites sarcoma.

IT 27069-13-2P 27069-15-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 27069-13-2 CAPLUS
CN Glycine, N-[[5-(p-methoxyphenyl)pyrazol-3-yl]carbonyl]-, hydrazide (8CI) (CA INDEX NAME)



RN 27069-15-4 CAPLUS

CN Glycine, N-[[5-(p-methoxyphenyl)pyrazol-3-yl]carbonyl]- (8CI) (CA INDEX NAME)



=>
=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	58.14	236.92

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.80	-4.80

STN INTERNATIONAL LOGOFF AT 14:41:02 ON 11 FEB 2008